Clinical trial NCT05148195: A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
Official title: An Open Label, Multi-cohort, Multicenter Phase II Study to Evaluate the Efficacy and Safety of Envofolimab in Combination With BD0801 Injection With/Without Chemotherapy in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Advanced Solid Tumor
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-12-08
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an open label, multi-cohort, multicenter Phase II study, the purpose of this study is to assess the efficacy and safety of envofolimab in combination with BD0801 injection with/without chemotherapy for the treatment of advanced solid tumors

Detailed description: The efficacy of immune checkpoint inhibitors combined with antivascular agents has been preliminarily demonstrated in a variety of solid tumors. Based on the huge clinical needs, the efficacy of envofolimab combined with BD0801 in patients with advanced hepatocellular carcinoma, non-small cell lung cancer and advanced colorectal cancer deserves further exploration.

Eligibility criteria: Inclusion Criteria:

1. Patients voluntarily signed informed consent;
2. Age≥18 age years old, male or female;
3. Patients diagnosed with unresectable or advanced solid tumors confirmed by histopathology or cytology; Cohort A: Patients must have progressed on standard of therapy, patients with NSCLC, CRC and HCC (include intrahepatic cholangiocarcinoma or mixed hepatocellular carcinoma-cholangiocarcinoma in safety run-in phase) are enrolled preferentially; Cohort B: Patients with histopathologically or cytologically or clinically diagnosed advanced HCC (Barcelona Clinic Liver Cancer (BCLC) Stage C; or BCLC Stage B patients who are not suitable for locoregional therapy (such as TACE) may also be enrolled), Child-Pugh liver function grade A and patients received at least one standard first-line systemic treatment and no more than 3 systemic regimens for HCC; Cohort C: Histologically confirmed NSCLC (except for patients with central and cavernous lung squamous cell carcinoma). Patients received at least one standard first line systemic treatment are required, if patients with EGFR、ALK or ROS1 gene positive, first line of target therapy will be required ( if patients with known EGFR mutation, they should be T790M negative or with osimertinib treatment failure); C1: Required prior anti-PD-1/PD-L1 therapy. C2: Never used prior anti-PD-1/PD-L1 therapy. Cohort D: Patients with advanced CRC confirmed with histology, the results of tissue samples must meet any of the following (1. the test result of immunohistochemistry is mismatch repair protein integrity (pMMR) 2. the test result of NGS is MSI-L or MSS 3 the test of result of PCR is MSI-L or MSS). Has received the oxaliplatin and 5-Fu containing regimen for the treatment of metastatic tumors.
4. ECOG score 0 or 1;
5. At least one measurable lesion as per RECIST V1.1;
6. Normal major organ and marrow functions as defined and no blood transfusion and blood product within 2 weeks before screening, no use of hematopoietic stimulating factors;
7. Life expectancy≥12 weeks;
8. Women of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose. Male or female patients of childbearing potential voluntarily use effective contraceptive methods from signing the informed consent form to 6 months after initiation of the study drug, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients are considered to be of childbearing potential unless they are postmenopausal (continuous menopause for 12 month), had undergone artificial menopause, or had undergone surgical sterilization (e.g., hysterectomy, surgical adnexectomy);

Exclusion Criteria:

1. Patients who have participated in clinical trials of other investigational drugs or investigational devices within 28 days prior to the first dose or received any systemic treatments within 2 weeks, include but not limited chemotherapy, radiotherapy (palliative radiotherapy is allowed at least 1 week before the study drug treatment), targeted therapy, Chinese herbal medicine or proprietary Chinese medicine for cancer control;
2. Patients with a history of Envofolimab or BD0801 treatment;
3. Patients who have ascites requiring drainage or diuretic treatment or pleural effusion or pericardial effusion requiring drainage and/or accompanied by shortness of breath within 2 weeks before the first dose of study drug treatment;
4. Cholangiocarcinoma, mixed cell carcinoma, or fibroblastic layer cell carcinoma are known for Cohort B;
5. Patients with other active malignancies within 2 years prior to the first administration of the study drug randomization, curable localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, and carcinoma in situ of the breast can be included in the group;
6. Patients whose toxicity and side effects (due to previous anticancer treatments) have not recovered to≤grade 1, unless such AE is not considered to pose safety risks (such as hair loss and neuropathy≤grade 2 caused by oxaliplatin)
7. Patients with previous and current central nervous system (CNS)metastasis;
8. Patients with a history of hepatic encephalopathy;
9. Patients with active tuberculosis (TB), who are receiving anti-TB treatment or received anti-TB treatment within 3 months prior the first study drug administration;
10. Abdominal fistula, gastrointestinal perforation, abdominal abscess and intestinal obstruction with clinical symptoms (including occlusive disease);
11. Receipt of live or attenuated live vaccines 4 weeks prior to the first study drug treatment;
12. Suffer from any disease that requires corticosteroids within 2 weeks prior to the first study drug administration, except for local corticosteroids or dose of prednisone or equivalent drugs≤ 10mg/ day;
13. Patients with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-associated pneumonia, and severe impairment of lung function that may interfere with the detection and management of suspected drug-related lung toxicity;
14. Patients with known activity or autoimmune diseases or history. Except subjects with vitiligoare not requiring systemic treatment within 2 years prior the first study drug, type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, pituitaritis and adrenal cortical insufficiency requiring only physiological hormone replacement therapy or psoriasis who do not require systemic treatment may be allowed;
15. Major surgery before enrollment or expected major surgery during the study period;
16. Severe unhealed wound, ulcers or fractures;
17. The current or recent (within 10 days before the first dose of study medication) use of aspirin for 10 days (\> 325 mg/day) or other known to inhibit platelet function of NSAIDs; a history bleeding disorders or thrombosis within 6 months before the first study drug administration;
18. Patients with clinically significant cardiovascular diseases；
19. Cardiac function: Left ventricular ejection fraction (LVEF)\<50%;
20. Human immunodeficiency virus (HIV) antibodies or acquired immune deficiency syndrome (AIDS);
21. Active hepatitis B (HBsAg positive and HBV- DNA ≥ULN) or hepatitis C (HCV antibody positive and quantitative HCV-RNA≥ULN);
22. Pregnant or lactating women during the study;
23. Patients with a history of allergy to studied drugs or similar drugs or excipients;
24. Other conditions that researchers consider inappropriate for inclusion;

Primary outcomes:
measure: Part I: MTD（Maximum tolerable dose）or RD（Recommended dose）
timeFrame: 6 months
measure: Part II: ORR(Objective Response Rate ) by investigator
timeFrame: 1.5 years
Secondary outcomes:
measure: DOR(Duration Of Response) by investigator
timeFrame: 1.5 years
measure: PFS(Progression Free Survival) by investigator
timeFrame: 1.5 years
measure: DCR(Disease Control Rate) by investigator
timeFrame: 1.5 years
measure: OS（Overall Survival)
timeFrame: 2.5 years
measure: The incidence of AEs（adverse events) and SAEs（serious adverse events)
timeFrame: 2 years
measure: ORR in subgroup of different TMB、PDL-1 and MSI status
timeFrame: 1.5 years
Other outcomes:
measure: PK(pharmacokinetics) of envofolimab and BD0801
timeFrame: 1.5 years
measure: Positive rate of ADA(anti-drug antibody)
timeFrame: 1.5 years
measure: Duration of immunogenicity positive reaction
timeFrame: 1.5 years
Locations:
city: Beijing
country: China
facility: Beijing Cancer Hospital
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical College
city: Changchun
country: China
facility: Jilin Cancer Hospital
city: Changsha
country: China
facility: Hunan Cancer Hospital
city: Chengdu
country: China
facility: Sichuan Cancer Hospital
city: Dezhou
country: China
facility: Dezhou People'S Hospital
city: Ganzhou
country: China
facility: First Affiliated Hospital of Gannan Medical Universit
city: Guangzhou
country: China
facility: Nanfang Hospital of Southern Medical University
city: Guangzhou
country: China
facility: Sun Yat-sen University affiliated with the Sixth Hospital
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Center
city: Hangzhou
country: China
facility: Shaw Hospital Affiliated to Medical College of Zhejiang Universit
city: Hangzhou
country: China
facility: Zhejiang Provincial People'S Hospital
city: Harbin
country: China
facility: Harbin Medical University Cancer Hospital
city: Hefei
country: China
facility: Anhui Chest Hospital
city: Hefei
country: China
facility: Anhui Provincial Cancer Hospital
city: Hefei
country: China
facility: The First Affliated Hospital Of Anhui Medical University
city: Jinan
country: China
facility: Shandong Cancer Hospital
city: Mianyang
country: China
facility: Mianyang Central Hospital
city: Shenyang
country: China
facility: Liaoning Cancer Hospital
city: Shijia Zhuang
country: China
facility: The Fourth Hospital of Hebei Medical University
city: Wuhan
country: China
facility: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
city: Yantai
country: China
facility: Yantai Yuhuagnding Hospital
city: Zhengzhou
country: China
facility: Henan Cancer Hospital
city: Zhengzhou
country: China
facility: The First Affiliated Hospital of Zhengzhou University
Study officials:
affiliation: Jiangsu Simcere Pharmaceutical Co., Ltd.
name: Zhengguang Lv
role: STUDY_DIRECTOR
References: